Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEMPA: PK of Mycophenolate Mofetil in Autoimmune Bullous Dermatoses
NCT02993133Phase 3Completed
- Sponsor
- CHU de Limoges
- Start
- Dec 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate mofetil in pemphigus and cicatricial pemphigoid (CP), sponsored by CHU de Limoges. Primary endpoint: Evaluation of the Bayesian estimator performance at 8 hours. Started Dec 2016; status: completed.
02
Drugs
mycophenolate mofetil
03
Conditions
pemphiguscicatricial pemphigoid (CP)
Beyond the preview
Go deeper on NCT02993133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993133.